Ensign Peak Advisors’s Janux Therapeutics JANX Stock Holding History

Ensign Peak Advisors’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$127K	Buy	8,250 +3,500	+74%	+$50.7K	﹤0.01%	1552
2026 Q1	$66K	Hold	4,750	–	–	﹤0.01%	1654
2025 Q4	$65.5K	Sell	4,750 -4,550	-49%	-$107K	﹤0.01%	1647
2025 Q3	$227K	Hold	9,300	–	–	﹤0.01%	1632
2025 Q2	$215K	Sell	9,300 -285,450	-97%	-$7.52M	﹤0.01%	1677
2025 Q1	$7.96M	Buy	294,750 +152,450	+107%	+$5.75M	0.02%	522
2024 Q4	$7.62M	Buy	142,300 +9,300	+7%	+$492K	0.01%	541
2024 Q3	$6.04M	Hold	133,000	–	–	0.01%	569
2024 Q2	$5.57M	Buy	+133,000	New	+$6.24M	0.01%	595

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Ensign Peak Advisors's JANX Position: Q2 2026 in Review

Ensign Peak Advisors increased its Janux Therapeutics (JANX) stake by 74% in Q2 2026, buying an estimated $50.7K and bringing the position to 8,250 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1552.

Ensign Peak Advisors first reported a position in JANX in Q2 2024 and has held it in 9 quarters since. The position peaked at $7.96M in Q1 2025. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Ensign Peak Advisors held 8,250 shares of Janux Therapeutics worth $127K as of Q2 2026.
Ensign Peak Advisors bought 3,500 Janux Therapeutics shares in Q2 2026, an estimated $50.7K.
Janux Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1552 holding.
Ensign Peak Advisors first reported a position in Janux Therapeutics in Q2 2024 and has held it in 9 quarters since.
Ensign Peak Advisors's Janux Therapeutics position peaked at $7.96M in Q1 2025.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.